



GNI Group Ltd. Ranks 5th in the 14th Deloitte Touche Tohmatsu LLC Japan Technology Fast50, A Ranking Program of Fastest-Growing Technology Companies

October, 19 2016 - GNI Group Ltd., (TSE Mothers listed code: 2160) a leading biopharmaceutical company listed in Japan, announced today that it ranked 5th in the 14th Japan Technology Fast50 with revenue growth of 453.74% based on past three according periods. Japan Technology Fast50, announced annually by Deloitte Touche Tohmatsu LLC, is a ranking of the 50 fastest-growing Japanese companies in the technology, media, and telecommunications (TMT) industries based on their revenue (sales) growth percentage based on the last three accounting periods. (<http://www2.deloitte.com/jp/ja/pages/about-deloitte/articles/news-releases/nr20161019.html>)

Japan Technology Fast50 is a Japanese edition of the ranking program series of TMT industries compiled by Deloitte Touche Tohmatsu Limited (DTTL) for about 40 countries as well as for three regions: North America, EMEA and Asia-Pacific. It has been serving as a benchmark for growth potential and success for corporations in the TMT industries. Companies, both listed and unlisted, are eligible to apply for Fast50 and the top 50 companies that have demonstrated exceptional growth in revenues (sales) based on the last three accounting periods are announced each year. Please visit <http://www.deloitte.com/jp/fast50> for further information on the program.

About GNI Group Ltd.

GNI Group Ltd. is a multinational biopharmaceutical company focused on research, development, manufacture, and commercialization of therapeutic agents for endemic diseases in Asia and worldwide. In addition to its CFDA Class 1.1 approved drug Etuary®, the only approved therapy for Idiopathic Pulmonary Fibrosis in China, GNI Group Ltd. has a robust drug development pipeline focused on innovative therapeutic agents for diseases including radiation pneumonitis, diabetic nephropathy, liver fibrosis (cirrhosis), acute-on-chronic liver failure (ACLF) and acute promyelocytic leukemia (APL). GNI Group Ltd. is listed on the Tokyo Stock Exchange Mothers Market, Code 2160, with headquarters in Tokyo and subsidiaries in Hong Kong, Shanghai, Beijing and the United States. For further information, please visit www.gnipharma.com.

For further inquiries

+81 (03) -6214-3600

Email: infojapan@gnipharma.com

This press release contains "forward-looking" statements, including statements related to our group's plans to pursue development of product candidates and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "continue," "expected to", "will" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause our group's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates. Our group does not undertake any obligation to update forward-looking statements.